Business Update

Aethlon Medical signs government research alliance

Published in Medical Letter on the CDC and FDA, February 25th, 2007

Aethlon Medical, Inc. (AEMD) announced that research related to the Aethlon Hemopurifier as a potential treatment for Ebola Hemorrhagic Fever (EHF) has been initiated at The Centers for Disease Control and Prevention (CDC).

EHF is classified as a category "A" bioterror threat presently untreatable with antiviral drug and vaccine therapy. According to the World Health Organization (WHO), EHF causes death in 50-90% of all clinically ill cases. The CDC is recognized globally for its research initiatives to prevent and control infectious disease. It operates as a primary component of the Department of Health and Human Services (HHS), the principal agency in the United...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-02-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry